Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone ...

Immatics has shared new survival data from a Phase 1b trial of its melanoma cell therapy candidate, bolstering expectations for a registrational study that it recently started.

Since Bernard Rav­ina’s med­ical train­ing in neu­rol­o­gy in the 1990s, there have been few new ther­a­pies that treat a move­ment dis­or­der known as dys­to­nia. … ...

Ei­sai and Mer­ck suc­ceed­ed in stop­ping Shilpa Medicare Ltd. from launch­ing a gener­ic ver­sion of Lenvi­ma for at least an­oth­er decade, Ei­sai said Thurs­day. … ...

It may not come as a sur­prise that one of the most un­con­ven­tion­al US sen­a­tors in re­cent mem­o­ry has tak­en a keen in­ter­est in a … ...

The US Supreme Court will con­tin­ue de­cid­ing whether to take up a piv­otal case on state PBM reg­u­la­tion af­ter the fed­er­al gov­ern­ment of­fered its stance … ...

Pep­Gen is aban­don­ing its ex­on 51-skip­ping Duchenne mus­cu­lar dy­s­tro­phy can­di­date af­ter it failed a Phase 2 tri­al. And it is get­ting out of the dis­ease … ...